Ramipril
- Generic Name
- Ramipril
- Brand Names
- Altace, Altace HCT
- Drug Type
- Small Molecule
- Chemical Formula
- C23H32N2O5
- CAS Number
- 87333-19-5
- Unique Ingredient Identifier
- L35JN3I7SJ
- Background
Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure...
- Indication
For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high ...
- Associated Conditions
- Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hearth Failure With Reduced Ejection Fraction (HFrEF), Hypertension, Myocardial Infarction, Nondiabetic proteinuric chronic kidney disease, Stroke, High risk cardiovascular event
- Associated Therapies
- -
To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2013-01-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT01302899
- Locations
- 🇳🇱
Novartis Investigative Site, Leeuwarden, Netherlands
Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 23
- Registration Number
- NCT01284621
- Locations
- 🇩🇪
1245.45.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 6
- Registration Number
- NCT01234922
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic and Hypertensive Patients With Microalbuminuria
- Conditions
- Interventions
- First Posted Date
- 2010-10-28
- Last Posted Date
- 2010-10-28
- Lead Sponsor
- University of Pavia
- Target Recruit Count
- 206
- Registration Number
- NCT01230034
- Locations
- 🇮🇹
University of Pavia, Pavia, Italy
Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial
- Conditions
- Interventions
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2010-10-21
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 60
- Registration Number
- NCT01225445
- Locations
- 🇭🇰
Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong
Intensive Vasodilator Therapy in Patients With Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Aarhus University Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT01180413
- Locations
- 🇩🇰
Aarhus University Hospital - dept. cardiology (A), Aarhus, Denmark
Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited, Under Non-Fasting Conditions
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2010-07-19
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 54
- Registration Number
- NCT01164774
- Locations
- 🇮🇳
Lambda Therapeutic Research Limited, Ahmedabad, Gujrat, India
Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited Under Fasting Conditions
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2010-07-19
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 54
- Registration Number
- NCT01164761
- Locations
- 🇮🇳
Lambda Therapeutic Research Limited, Ahmedabad, Gujrat, India
Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy
- Conditions
- Interventions
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 96
- Registration Number
- NCT01078363
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸VA Palo Alto Health Care System, Palo Alto, California, United States
Ramipril 10 mg/Day Prevention
- First Posted Date
- 2010-01-22
- Last Posted Date
- 2010-01-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1012
- Registration Number
- NCT01053910
- Locations
- 🇧🇩
Sanofi-Aventis Administrative Office, Dhaka, Bangladesh
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.